How India Exports Device to the World

In the United States, pharmaceutical products under HS Code 30049099 are subject to the Food and Drug Administration's (FDA) regulatory oversight. The FDA's Orange Book, officially titled "Approved Drug Products with Therapeutic Equivalence Evaluations," lists approved drug products along with their therapeutic equivalence evaluations. Manufacturers seeking to market generic versions of these products must submit Abbreviated New Drug Applications (ANDAs) to demonstrate bioequivalence to the reference listed drug (RLD). The Orange Book also provides information on patents and exclusivity periods, which are critical for determining the timing of generic market entry.

Given the presence of 154 active Indian exporters and a total of 2,752 shipment records, it is evident that Indian manufacturers are significant contributors to the U.S. pharmaceutical market. However, to ensure compliance with FDA regulations, these exporters must adhere to stringent requirements, including Good Manufacturing Practices (GMP), accurate labeling, and timely reporting of adverse events. Additionally, any import alerts issued by the FDA can impact the ability of Indian exporters to supply the U.S. market, underscoring the importance of maintaining high-quality standards.

In the European Union (EU) and the United Kingdom (UK), pharmaceutical products are regulated by the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Marketing authorization is mandatory before any medicinal product can be marketed in these regions. The EMA and MHRA require comprehensive data on quality, safety, and efficacy, and adherence to EU Good Manufacturing Practice (GMP) guidelines is essential. These guidelines ensure that products are consistently produced and controlled to the quality standards appropriate for their intended use.

For Indian exporters, compliance with EU GMP is crucial, as non-compliance can lead to the refusal of marketing authorization or withdrawal of existing authorizations. Regular inspections and audits are conducted to verify adherence to these standards, and any deficiencies must be promptly addressed to maintain market access.

The World Health Organization (WHO) maintains the Model List of Essential Medicines, which serves as a guide for the development of national and institutional essential medicine lists. Inclusion in this list indicates a medicine's importance in a basic health system. Additionally, the WHO Prequalification Programme assesses the quality, safety, and efficacy of medicinal products, providing a list of prequalified products that meet global standards.

Pharmaceutical products must also comply with pharmacopoeial standards, such as those outlined in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These standards specify the quality requirements for medicinal substances and products, ensuring consistency and safety in their use.

In India, the Central Drugs Standard Control Organization (CDSCO) classifies drugs into various schedules under the Drugs and Cosmetics Act. Products under HS Code 30049099 are typically classified under Schedule H, H1, or X, indicating their prescription status and control measures. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines under the Drugs (Prices Control) Order (DPCO). For instance, on November 4, 2025, the NPPA revised the ceiling prices of several key medicines under DPCO 2013, impacting the pricing strategies of manufacturers and exporters.

Exporters are also required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of certain pharmaceutical products. This ensures that domestic supply is not adversely affected by exports and that the products meet the regulatory requirements of the importing countries.

The patent status of pharmaceutical products significantly influences market dynamics. Patents grant the holder exclusive rights to market the product for a specified period, typically 20 years from the filing date. Once patents expire, generic manufacturers can enter the market, leading to increased competition and reduced prices. The FDA's Orange Book provides information on patents and exclusivity periods, which are critical for determining the timing of generic market entry.

In November 2025, the NPPA revised the ceiling prices of several key medicines under the DPCO 2013, impacting the pricing strategies of manufacturers and exporters.

In January 2026, the FDA introduced updates to the Orange Book to clarify the identification of reference listed drugs (RLDs) and reference standards, aiding generic manufacturers in their ANDA submissions.

In March 2026, the EMA issued new guidelines on the assessment of bioequivalence studies, affecting the approval process for generic medicines in the EU.

In February 2026, the WHO updated its Model List of Essential Medicines, adding new treatments for chronic diseases, which may influence the demand for certain pharmaceutical exports.

In December 2025, the CDSCO implemented stricter regulations on the import of active pharmaceutical ingredients (APIs), affecting the supply chain for Indian manufacturers.

These developments underscore the dynamic nature of the pharmaceutical regulatory environment and the need for exporters to stay informed and compliant with evolving standards and requirements.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). Approximately 60–70% of India's APIs are sourced from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese production—due to environmental regulations, geopolitical tensions, or other factors—can lead to shortages and price volatility in the Indian pharmaceutical sector.

In response to these challenges, the Indian government has initiated measures to bolster domestic API production. In October 2024, two greenfield plants were inaugurated under the Production Linked Incentive (PLI) scheme, aiming to manufacture critical molecules like Penicillin G, 6-APA, and Clavulanic Acid, which are essential for common antibiotics. These efforts are part of a broader strategy to reduce import dependence on key pharmaceutical ingredients.

Our proprietary trade data indicates a high supplier concentration for the export of "Device" from India. The top five exporters account for 90.0% of total exports, with CORPORATE CHANNELS (INDIA) PVT. LTD alone contributing 31.8% ($7.8M USD). Such concentration poses a significant single-source risk; any operational or financial issues faced by these key suppliers could disrupt the entire supply chain.

The PLI scheme, launched by the Indian government, aims to mitigate these risks by incentivizing domestic production of APIs and KSMs. By reducing reliance on a limited number of suppliers and encouraging diversification, the scheme seeks to enhance the resilience of the pharmaceutical supply chain.

Recent geopolitical events have further strained the pharmaceutical supply chain. The closure of the Strait of Hormuz in March 2026, following military conflicts involving Iran, has disrupted global shipping routes. This chokepoint is vital for the transportation of oil and other goods, including pharmaceuticals. The blockade has led to increased shipping costs and delays, affecting the timely delivery of pharmaceutical products.

Additionally, tensions in the Red Sea and the Suez Canal have compelled shipping companies to reroute vessels around Africa's Cape of Good Hope, adding significant transit time and costs. These disruptions have cascading effects on the availability and pricing of pharmaceutical products globally.

• Diversify Supplier Base: Encourage partnerships with multiple suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Invest in local manufacturing capabilities for APIs and KSMs to decrease reliance on imports.

• Strengthen Supply Chain Monitoring: Implement robust systems to monitor geopolitical developments and shipping routes, allowing for proactive adjustments.

• Develop Contingency Plans: Establish alternative logistics and transportation strategies to mitigate the impact of shipping disruptions.

• Engage in Policy Advocacy: Collaborate with industry associations and government bodies to advocate for policies that support supply chain resilience.

RISK_LEVEL: HIGH